Penny Vandestreek, DO
Nuclear Medicine · Roseville, CANPI 1164463402
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $336 of the $516 with a category attached, or 65.1%. 5 manufacturers reported payments, led by Astellas Pharma US Inc at 34.9% of the total. Reporting peaked in 2019 at $241 and has fallen 89.1% since, to $26 in 2025.
Across 7 payments — averaging $73.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$180
- Siemens Medical Solutions USA, Inc.$126
- Advanced Accelerator Applications$115
- Progenics Pharmaceuticals, Inc.$80
- Boston Scientific$15
What the payments were for
- Food & beverage$33665%
- Education$18035%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 2 | $180 |
| Siemens Medical Solutions USA, Inc. | 1 | $126 |
| Advanced Accelerator Applications | 1 | $115 |
| Progenics Pharmaceuticals, Inc. | 2 | $80 |
| Boston Scientific | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOMATOM Force$126
- Lutathera$115
How this compares
$516 in reported general payments places this provider in the 80th percentile of 110 nuclear medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ondansetron OdtOndansetron | 22 | $268 |
Paid to pharmacies, not to this prescriber.
Other nuclear medicine in Roseville
- Jonathan GershensonRoseville$461
- Hossein JadvarLos Angeles$294K
- Michael DaeSan Francisco$45K
- Ernest BelezzuoliSan Diego$39K
- Johannes CzerninLos Angeles$24K
- Gholam BerenjiLos Angeles$15K
- Frankis AlmaguelSan Bernardino$13K
- Shahram BonyadlouLos Angeles$12K
- Leonard ValentinoRedwood City$8K
- Randy YehSylmar$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.